Nutex Health
Nutex Health's revenue rose 82.4% to $875 million in fiscal 2025. Its operating margin was 31.5%, up from 27.2% a year earlier. Free cash flow was $246 million, up 1078.0%. It paid out $5 million in dividends and buybacks, 2% of free cash flow. The diluted share count rose 23.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Nutex Health does
Nutex Health is a healthcare company based in Houston, run by doctors. At the end of 2025 it owned and ran 26 hospital facilities in 12 states, with nine more micro-hospitals in development. Micro-hospitals are small hospitals with emergency rooms, a few inpatient beds and on-site imaging, labs and pharmacy. It has 944 full-time employees and contracts more than 280 doctors at its facilities.
It reports three segments. The hospital division builds and runs micro-hospitals, specialty hospitals and hospital outpatient departments, and provides emergency, inpatient and behavioral health care. Most of its hospitals are out-of-network with insurers, which means they do not have negotiated rates with most insurance companies. The population health division owns and runs provider networks, such as independent physician associations, that take on the financial risk of caring for groups of patients. The real estate division holds property used by its hospitals.
Nutex gets paid for patient care by insurers, government programs and patients. It also runs the business side for each hospital, including billing, staffing and compliance. Most hospitals have contracts with separately owned doctor groups and property companies, some owned in part by its chairman and chief executive. Nutex says it expects to contract directly with more commercial insurers in the future.
Its biggest risks, as it describes them
- Uncertainty and lawsuits over the No Surprises Act's payment dispute process, which may cut cash it collects.
- Relying on an outside company, HaloMD, in that dispute process, and having no right to audit its data.
- Being mostly out of network with insurers, so it has no negotiated payment rates with most of them.
- Issuing more shares to former doctor owners of new hospitals, which would dilute current shareholders.
- Write-offs or impairment charges, and past weaknesses in its financial reporting controls.
Income statement
From fiscal 2017 to 2025, earnings per share grew 138.5% a year and net income 81.5% a year, as buybacks cut the share count by 92%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 36 | 34 | 22 | 41 | 186 |
| Debt incl. finance leases | 156 | 243 | 255 | 304 | 318 |
| Net debt (negative means net cash) | 120 | 209 | 233 | 263 | 133 |
| Net debt to EBITDA | 0.7x | — | — | 1.8x | 0.5x |
| Debt to equity | 1.4x | 2.5x | 4.2x | 2.3x | 1.0x |
| Interest coverage | 27.5x | −32.5x | −1.9x | 6.6x | 12.4x |
| Current ratio | 4.1x | 1.8x | 1.6x | 1.9x | 3.4x |
| Quick ratio | 4.0x | 1.7x | 1.5x | 1.9x | 3.4x |
Cash flow
Projections
Project Nutex Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Nutex Health reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 7 of 9 | 7 of 9 |
| Rule of 40 | 9.6% | 98.2% | 110.4% |
| Altman Z'' | −3.09 | 1.37 | 4.62 |
| Accruals ratio | −11.3% | 5.5% | −22.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | 7 of 9 | 7 of 9 |
Compare
Put Nutex Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Nutex Health | FY25 | 82.4% | 31.5% | 28.1% | 40.3% | 0.5x | 7 | |
| U.S. Physical Therapy | FY25 | 16.3% | 11.1% | 7.8% | 10.7% | 1.2x | 6 | Compare |
| National Healthcare | FY25 | 16.1% | 8.5% | 9.8% | 9.4% | −0.3x | 6 | Compare |
| Sonida Senior Living | FY25 | 25.2% | — | −2.3% | −3.8% | 29.2x | 3 | Compare |
| Astrana Health | FY25 | 56.4% | 2.5% | 3.3% | 4.2% | 4.9x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 1 | 1 | 274 | 332 | 219 | 248 | 480 | 875 |
| Revenue growth | −100.0% | — | 5,800.9% | −0.0% | 19,954.5% | 21.0% | −33.9% | 12.9% | 93.8% | 82.4% |
| Gross profit | 0 | −0 | 1 | 0 | 158 | 179 | 15 | 35 | 196 | 444 |
| Research and development | — | — | 0 | 1 | 1 | 0 | — | — | — | — |
| Operating income | −0 | −6 | −1 | −7 | 153 | 170 | −407 | −32 | 131 | 276 |
| Net income | −7 | 1 | −1 | −7 | 106 | 133 | −425 | −46 | 52 | 71 |
| Diluted EPS (US$) | −0.19 | 0.01 | −0.56 | −1.96 | 0.18 | 0.22 | −100.36 | −10.39 | 9.69 | 10.48 |
| Diluted shares (millions) | 40 | 84 | 2 | 4 | 5 | 593 | 4 | 4 | 6 | 7 |
| Cash flow | ||||||||||
| Cash from operations | −0 | −1 | −0 | −4 | 87 | 173 | 51 | 1 | 23 | 248 |
| Capital expenditure | — | — | 0 | 0 | 61 | 37 | 15 | 10 | 2 | 2 |
| Free cash flow | — | — | −0 | −4 | 25 | 137 | 36 | −8 | 21 | 246 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 0 | 0 | 3 | 4 | 0 | — | −0 | 108 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 0 | 0 | 0 | 1 | 0 | 36 | 34 | 22 | 41 | 186 |
| Debt incl. finance leases | — | — | 0 | 0 | 0 | 156 | 243 | 255 | 304 | 318 |
| Total assets | 0 | 3 | 0 | 7 | 0 | 395 | 432 | 398 | 655 | 918 |
| Total liabilities | 6 | 4 | 2 | 5 | 1 | 203 | 311 | 319 | 467 | 495 |
| Shareholders' equity | −6 | −1 | −2 | 2 | −1 | 115 | 96 | 62 | 132 | 329 |
| Margins and ratios | ||||||||||
| Gross margin | — | −31.6% | 62.9% | 39.2% | 57.5% | 54.1% | 7.0% | 14.0% | 40.9% | 50.8% |
| Operating margin | — | −24,574.5% | −61.5% | −504.8% | 55.9% | 51.4% | −185.4% | −12.8% | 27.2% | 31.5% |
| Net margin | — | 2,512.6% | −69.5% | −520.8% | 38.7% | 40.0% | −193.7% | −18.5% | 10.8% | 8.1% |
| Free cash flow margin | — | — | −35.1% | −301.9% | 9.3% | 41.2% | 16.4% | −3.3% | 4.3% | 28.1% |
| Rule of 40 (growth + FCF margin) | — | — | 5,765.8% | −301.9% | 19,963.8% | 62.2% | −17.4% | 9.6% | 98.2% | 110.4% |
| Return on capital | — | — | — | −22.5% | 155.2% | 73.8% | −100.2% | −7.8% | 29.5% | 40.3% |
| Return on equity | — | — | — | −3,941.8% | 29,247.7% | 233.6% | −403.6% | −58.2% | 53.7% | 30.6% |
| Return on assets | −182.4% | 30.3% | −50.3% | −199.3% | 3,088.4% | 67.2% | −102.8% | −11.0% | 9.9% | 9.0% |
| Net debt to EBITDA | — | — | — | — | −0.0x | 0.7x | — | — | 1.8x | 0.5x |